<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02213289</url>
  </required_header>
  <id_info>
    <org_study_id>IRB14-0141</org_study_id>
    <nct_id>NCT02213289</nct_id>
  </id_info>
  <brief_title>PANGEA-IMBBP: Personalized Antibodies for Gastro-Esophageal Adenocarcinoma - A 1st Pilot Metastatic Trial of Biologics Beyond Progression</brief_title>
  <official_title>PANGEA: Personalized Antibodies for Gastro-Esophageal Adenocarcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Chicago</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Chicago</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if doctors can use the results of special tests of&#xD;
      subjects tumor tissue, that will look for specific abnormalities in the tumor, to choose a&#xD;
      specific drug that is targeted to work against that abnormality (called molecular profiling)&#xD;
      and to see what effects (good and/or bad) that targeted drug has on subjects cancer when it&#xD;
      is given with standard chemotherapy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 20, 2015</start_date>
  <completion_date type="Actual">August 20, 2020</completion_date>
  <primary_completion_date type="Actual">February 1, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Up to 60 months</time_frame>
    <description>Time from enrollment to death from any cause.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Biopsies Leading to an Adverse Event</measure>
    <time_frame>1 Month</time_frame>
    <description>Number of biopsies leading to an adverse event of the total undergoing baseline biopsies of a primary and metastatic disease site (liver, lung, lymph node, peritoneum/carcinomatosis).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Completion of Biopsy and Successful, Molecularly-based Treatment Assignment</measure>
    <time_frame>Up to 1 month</time_frame>
    <description>Completion of biopsies with successful assignment per the treatment algorithm. Biomarker profile assays included next generation sequencing (NGS). EGFR expression was performed by selected-reaction-monitoring mass spectrometry (SRM-MS).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Event From Serial Biopsy for Second-line Treatment</measure>
    <time_frame>Up to 60 Months</time_frame>
    <description>Number of participants with adverse events from serial biopsies of progressing metastatic disease sites (liver, lung, lymph node, peritoneum/carcinomatosis)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Completion of Serial Biopsy for Second Line Therapy and Successful, Molecularly-based Treatment Assignment</measure>
    <time_frame>Up to 60 months</time_frame>
    <description>Completion of biopsy with successful treatment assignment per the treatment algorithm. Biomarker profile assays included next generation sequencing (NGS). EGFR expression was performed by selected-reaction-monitoring mass spectrometry (SRM-MS).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Event From Serial Biopsy for Third-line Treatment</measure>
    <time_frame>Up to 60 months</time_frame>
    <description>Number of participants with adverse events from serial biopsies of progressing metastatic disease sites (liver, lung, lymph node, peritoneum/carcinomatosis)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Completion of Serial Biopsy for Third Line Therapy and Successful, Molecularly-based Treatment Assignment</measure>
    <time_frame>Up to 60 months</time_frame>
    <description>Completion of biopsy with successful treatment assignment per the treatment algorithm. Biomarker profile assays included next generation sequencing (NGS). EGFR expression was performed by selected-reaction-monitoring mass spectrometry (SRM-MS).</description>
  </secondary_outcome>
  <other_outcome>
    <measure>First-line Progression-free Survival</measure>
    <time_frame>Up to 60 Months</time_frame>
    <description>Time from enrollment to progression or death during first-line treatment. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.</description>
  </other_outcome>
  <other_outcome>
    <measure>Objective Response to First Line Therapy</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by CT or MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.</description>
  </other_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>ITT-PTS: Personalized Treatment Strategy (Immuno-oncology)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>For patients with monclonal antibiodies available, initial therapy was tailored based on biomarker profile as follows:&#xD;
Immuno-oncology included PD-L1 IHC combined positivity score &gt;10, high microsatellite instability, tumor mutation burden &gt;15 mutations per megabase, and/or Epstein-Barr virus positive. These patients received standard cytotherapy plus Nivolumab.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ITT-PTS: Personalized Treatment Strategy (HER2 amplified)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HER2 amplified. These patients received standard cytotherapy plus Trastuzumab.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ITT-PTS: Personalized Treatment Strategy (EFGR amplified)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>EGFR amplified. These patients received ABT-806.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ITT-PTS: Personalized Treatment Strategy (FGFR2 amplified)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FGFR2 amplified. These patients received standard cytotherapy plus Bemarituzumab.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ITT-PTS: Personalized Treatment Strategy (MAPK/PIK3CA aberrant)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MAPK/PIK3CA aberrant. These patients received standard cytotherapy plus Ramucirumab.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ITT-PTS: Personalized Treatment Strategy (EGFR expressing)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>EGFR expressing. These patients received standard cytotherapy plus ABT 806.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ITT-PTS: Personalized Treatment Strategy (All negative)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All negative. These patients received standard cytotherapy plus Ramucirumab.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-ITT: Standard Therapy</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients without monoclonal antibodies available received standard cytotherapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trastuzumab</intervention_name>
    <description>Trastuzumab</description>
    <arm_group_label>ITT-PTS: Personalized Treatment Strategy (HER2 amplified)</arm_group_label>
    <other_name>Herceptin®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABT-806</intervention_name>
    <description>ABT-806</description>
    <arm_group_label>ITT-PTS: Personalized Treatment Strategy (EFGR amplified)</arm_group_label>
    <arm_group_label>ITT-PTS: Personalized Treatment Strategy (EGFR expressing)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bemarituzumab</intervention_name>
    <description>Bemarituzumab</description>
    <arm_group_label>ITT-PTS: Personalized Treatment Strategy (FGFR2 amplified)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ramucirumab</intervention_name>
    <description>Ramucirumab</description>
    <arm_group_label>ITT-PTS: Personalized Treatment Strategy (All negative)</arm_group_label>
    <arm_group_label>ITT-PTS: Personalized Treatment Strategy (MAPK/PIK3CA aberrant)</arm_group_label>
    <other_name>Cyramza</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nivolumab</intervention_name>
    <description>Nivolumab</description>
    <arm_group_label>ITT-PTS: Personalized Treatment Strategy (Immuno-oncology)</arm_group_label>
    <other_name>Opdivo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard cytotherapy</intervention_name>
    <description>FOLFOX (First Line) +FOLFIRI (Second Line) +FOLTAX (Third Line)</description>
    <arm_group_label>ITT-PTS: Personalized Treatment Strategy (All negative)</arm_group_label>
    <arm_group_label>ITT-PTS: Personalized Treatment Strategy (EFGR amplified)</arm_group_label>
    <arm_group_label>ITT-PTS: Personalized Treatment Strategy (EGFR expressing)</arm_group_label>
    <arm_group_label>ITT-PTS: Personalized Treatment Strategy (FGFR2 amplified)</arm_group_label>
    <arm_group_label>ITT-PTS: Personalized Treatment Strategy (HER2 amplified)</arm_group_label>
    <arm_group_label>ITT-PTS: Personalized Treatment Strategy (Immuno-oncology)</arm_group_label>
    <arm_group_label>ITT-PTS: Personalized Treatment Strategy (MAPK/PIK3CA aberrant)</arm_group_label>
    <arm_group_label>Non-ITT: Standard Therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Histologically confirmed metastatic gastric or esophagogastric junction (type I,II,III&#xD;
             Siewert) adenocarcinoma&#xD;
&#xD;
          2. Newly-diagnosed chemo-naïve or recurrent after curative-intent surgery&#xD;
&#xD;
               -  &gt;6 months after completion of adjuvant therapy (including chemotherapy and/or&#xD;
                  radiotherapy)&#xD;
&#xD;
               -  No prior treatment with any targeted agent&#xD;
&#xD;
               -  Patients who have started first line mFOLFOX6 therapy (+/-trastuzumab for HER2&#xD;
                  amplified tumors) may be considered for trial participation if they have received&#xD;
                  no more than 4 doses of therapy at the time of consent and screening.&#xD;
&#xD;
          3. Measurable metastatic disease by RECIST criteria,&#xD;
&#xD;
               -  Must be amenable to ultrasound or CT-guided biopsy of one metastatic lesion&#xD;
&#xD;
               -  Peritoneal disease as the sole site of occult metastasis or presenting as&#xD;
                  malignant ascites is acceptable if a cell block of tumor cells can be obtained&#xD;
                  showing &gt;20% viable tumor cells.&#xD;
&#xD;
          4. ECOG PS 0,1&#xD;
&#xD;
          5. Age &gt; 18 years&#xD;
&#xD;
          6. Patients must have normal organ and marrow function as defined below:&#xD;
&#xD;
               -  granulocytes &gt;1,2500/mcL&#xD;
&#xD;
               -  platelets &gt;100,000/mcL&#xD;
&#xD;
               -  total bilirubin &lt; 1.5 x ULN, &lt;1.8 x ULN with liver metastases&#xD;
&#xD;
               -  AST(SGOT)/ALT(SGPT) &lt;2.5 X ULN without liver metastases; &lt;5 X ULN with liver&#xD;
                  metastases&#xD;
&#xD;
               -  creatinine within normal institutional limits (&lt;1.5) OR&#xD;
&#xD;
               -  creatinine clearance &gt;50 mL/min/1.73m2, (for creatinine level above normal)&#xD;
&#xD;
               -  INR: &lt; 1.5 (patients on warfarin need to be converted to LMWH during study&#xD;
                  participation to be eligible)&#xD;
&#xD;
          7. Consent to baseline metastatic and progressive disease biopsy (of&#xD;
             metastatic/progressing lesion) for enabling biomarker assessment and treatment&#xD;
             assignment (at each time point - baseline, PD1, PD2, PD3) as well as for correlative&#xD;
             studies.&#xD;
&#xD;
             • Consent to baseline and serial blood draws for plasma/serum/whole blood banking for&#xD;
             correlative studies&#xD;
&#xD;
          8. Ability to understand and the willingness to sign a written informed consent document&#xD;
             and consent to the serial nature of the proposed PANGEA treatment with first, second&#xD;
             and third line therapy as tolerated.&#xD;
&#xD;
          9. Ability to comply with requirements of the protocol, as assessed by the investigator&#xD;
             by the patient signing the consent form.&#xD;
&#xD;
         10. If history of exposure to anthracyclines during perioperative treatment, the following&#xD;
             cumulative doses of anthracyclines must be less than:&#xD;
&#xD;
             Epirubicin &lt; 720 mg/m2 Doxorubicin or liposomal doxorubicin &lt; 360 mg/m2 Mitoxantrone &gt;&#xD;
             120 mg/m2 and idarubicin &gt; 90 mg/m2 If more than one anthracycline has been used, then&#xD;
             the cumulative dose must not exceed the equivalent of 360 mg/m2 of doxorubicin.&#xD;
&#xD;
         11. Cardiac Ejection Fraction &gt;50% (for HER2+ patients) as assessed by echocardiogram,&#xD;
             MUGA scan, or cardiac MRI&#xD;
&#xD;
         12. Willingness to use effective and reliable methods of contraception (For appropriate&#xD;
             methods of contraception considered acceptable see Appendix B).&#xD;
&#xD;
        Both men and women and members of all races and ethnic groups are eligible for this trial.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. No CVA within 6 months, no recent MI within 6 months&#xD;
&#xD;
          2. No currently active second malignancy&#xD;
&#xD;
          3. No uncontrolled intercurrent illness or infection&#xD;
&#xD;
          4. No peripheral edema &gt; grade 2 at baseline.&#xD;
&#xD;
          5. No peripheral neuropathy &gt; grade 2 at baseline.&#xD;
&#xD;
          6. No diarrhea &gt; grade 2 at baseline.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel Catenacci, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Chicago</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>August 1, 2014</study_first_submitted>
  <study_first_submitted_qc>August 8, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 11, 2014</study_first_posted>
  <results_first_submitted>January 29, 2021</results_first_submitted>
  <results_first_submitted_qc>March 15, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">April 8, 2021</results_first_posted>
  <last_update_submitted>March 15, 2021</last_update_submitted>
  <last_update_submitted_qc>March 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Gastric</keyword>
  <keyword>Esophagogastric</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nivolumab</mesh_term>
    <mesh_term>Trastuzumab</mesh_term>
    <mesh_term>Bemarituzumab</mesh_term>
    <mesh_term>Ramucirumab</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 19, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/89/NCT02213289/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>ITT-PTS: Personalized Treatment Strategy</title>
          <description>For patients with monoclonal antibiodies available, initial therapy was tailored based on biomarker profile as follows:&#xD;
Immuno-oncology patients including PD-L1 IHC combined positivity score &gt;10, high microsatellite instability, tumor mutation burden &gt;15 mutations/megabase, and/or Epstein-Barr virus positive received standard cytotherapy plus Nivolumab.&#xD;
HER2 amplified patients received standard cytotherapy plus Trastuzumab.&#xD;
EGFR amplified patients received standard cytotherapy plus ABT-806&#xD;
FGFR2 amplified patients received standard cytotherapy plus Bemarituzumab.&#xD;
MAPK/PIK3CA aberrant patients received standard cytotherapy plus Ramucirumab.&#xD;
EGFR expressing patients received standard cytotherapy plus ABT 806.&#xD;
All negative patients received standard cytotherapy plus Ramucirumab.&#xD;
Of note, while the protocol section describes these tailored therapies, the efficacy evaluation was based on pooling these treatments into a combined &quot;personalized treatment strategy&quot; group and comparing with historical controls. Therefore this &quot;arm&quot; includes all such patients with monoclonal antibodies available.</description>
        </group>
        <group group_id="P2">
          <title>Non-ITT: Standard Therapy</title>
          <description>For patients without monoclonal antibodies available. These patients received standard cytotherapy consisting of FOLFOX (First Line) +FOLFIRI (Second Line) +FOLTAX (Third Line)&#xD;
Of note, this arm includes patients without monoclonal antibodies available, for whom no personalized treatment strategy was available. The intent of the protocol was NOT to compare this arm with arm 1.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="68"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Immuno-oncology</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>HER2 Amplified</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>EGFR Amplified</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>FGFR2 Amplified</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>MAPK/PIK3CA Aberrant</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>EGFR Expressing</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>All Negative</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Other (Non-ITT)</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="68"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>ITT-PTS: Personalized Treatment Strategy</title>
          <description>For patients with monclonal antibiodies available, initial therapy was tailored based on biomarker profile as follows:&#xD;
Immuno-oncology patients including PD-L1 IHC combined positivity score &gt;10, high microsatellite instability, tumor mutation burden &gt;15 mutations/megabase, and/or Epstein-Barr virus positive patients received standard cytoptherapy plus Nivolumab&#xD;
HER2 amplified patients received standard cytotherapy plus Trastuzumab&#xD;
EGFR amplified patients received standard cytotherapy plus ABT-806&#xD;
FGFR2 amplified patients received standard cytotherapy plus Bemarituzumab&#xD;
MAPK/PIK3CA aberrant patients received standard cytotherapy plus Ramucirumab.&#xD;
EGFR expressing patients received standard cytotherapy plus ABT 806.&#xD;
All negative patients received standard cytotherapy plus Ramucirumab.</description>
        </group>
        <group group_id="B2">
          <title>Non-ITT: Standard Therapy</title>
          <description>For patients without monoclonal antibodies available, therapy was standard cytotherapy consisting of FOLFOX (First Line) +FOLFIRI (Second Line) +FOLTAX (Third Line)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="68"/>
            <count group_id="B2" value="12"/>
            <count group_id="B3" value="80"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61" lower_limit="28" upper_limit="81"/>
                    <measurement group_id="B2" value="61" lower_limit="39" upper_limit="77"/>
                    <measurement group_id="B3" value="61" lower_limit="28" upper_limit="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="53"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="57"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="68"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Overall Survival</title>
        <description>Time from enrollment to death from any cause.</description>
        <time_frame>Up to 60 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ITT-PTS: Personalized Treatment Strategy</title>
            <description>For patients with monclonal antibiodies available, initial therapy was tailored based on biomarker profile as follows:&#xD;
Immuno-oncology patients including PD-L1 IHC combined positivity score &gt;10, high microsatellite instability, tumor mutation burden &gt;15 mutations/megabase, and/or Epstein-Barr virus positive received standard cytotherapy plus Nivolumab.&#xD;
HER2 amplified patients received standard cytotherapy plus received Trastuzumab&#xD;
EGFR amplified patients received standard cytotherapy plus ABT-806&#xD;
FGFR2 amplified patients received standard cytotherapy plus Bemarituzumab.&#xD;
MAPK/PIK3CA aberrant patients received standard cytotherapy plus Ramucirumab.&#xD;
EGFR expressing patients received standard cytotherapy plus ABT 806.&#xD;
All negative patients received standard cytotherapy plus Ramucirumab.</description>
          </group>
          <group group_id="O2">
            <title>Non-ITT: Standard Therapy</title>
            <description>For patients without monoclonal antibodies available. These patients received standard cytotherapy consisting of FOLFOX (First Line) +FOLFIRI (Second Line) +FOLTAX (Third Line)</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <description>Time from enrollment to death from any cause.</description>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="68"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.7" lower_limit="13.4" upper_limit="17.7"/>
                    <measurement group_id="O2" value="9.0" lower_limit="4.6" upper_limit="20.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0024</p_value>
            <method>One-sided Z-test</method>
            <method_desc>This was a test of whether the observed 1-year survival rate was significantly different from historical 50% rate.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Biopsies Leading to an Adverse Event</title>
        <description>Number of biopsies leading to an adverse event of the total undergoing baseline biopsies of a primary and metastatic disease site (liver, lung, lymph node, peritoneum/carcinomatosis).</description>
        <time_frame>1 Month</time_frame>
        <population>Unit of analysis is the biopsy. Each patient had two biopsies, one of the primary tumor and one of a metastatic site.</population>
        <group_list>
          <group group_id="O1">
            <title>ITT-PTS: Personalized Treatment Strategy</title>
            <description>For patients with monclonal antibiodies available, initial therapy was tailored based on biomarker profile as follows:&#xD;
Immuno-oncology patients including PD-L1 IHC combined positivity score &gt;10, high microsatellite instability, tumor mutation burden &gt;15 mutations/megabase, and/or Epstein-Barr virus positive received standard cytotherapy plus Nivolumab.&#xD;
HER2 amplified patients received standard cytotherapy plus received Trastuzumab&#xD;
EGFR amplified patients received standard cytotherapy plus ABT-806&#xD;
FGFR2 amplified patients received standard cytotherapy plus Bemarituzumab.&#xD;
MAPK/PIK3CA aberrant patients received standard cytotherapy plus Ramucirumab.&#xD;
EGFR expressing patients received standard cytotherapy plus ABT 806.&#xD;
All negative patients received standard cytotherapy plus Ramucirumab.</description>
          </group>
          <group group_id="O2">
            <title>Non-ITT: Standard Therapy</title>
            <description>For patients without monoclonal antibodies available. These patients received standard cytotherapy consisting of FOLFOX (First Line) +FOLFIRI (Second Line) +FOLTAX (Third Line)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Biopsies Leading to an Adverse Event</title>
          <description>Number of biopsies leading to an adverse event of the total undergoing baseline biopsies of a primary and metastatic disease site (liver, lung, lymph node, peritoneum/carcinomatosis).</description>
          <population>Unit of analysis is the biopsy. Each patient had two biopsies, one of the primary tumor and one of a metastatic site.</population>
          <units>biopsies</units>
          <param>Number</param>
          <units_analyzed>Biopsies</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="68"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Biopsies</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="136"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Completion of Biopsy and Successful, Molecularly-based Treatment Assignment</title>
        <description>Completion of biopsies with successful assignment per the treatment algorithm. Biomarker profile assays included next generation sequencing (NGS). EGFR expression was performed by selected-reaction-monitoring mass spectrometry (SRM-MS).</description>
        <time_frame>Up to 1 month</time_frame>
        <population>Unit of analysis is the biopsy. Two biopsies were performed per patient, one of the primary tumor and one from a metastatic site.</population>
        <group_list>
          <group group_id="O1">
            <title>ITT-PTS: Personalized Treatment Strategy</title>
            <description>For patients with monclonal antibiodies available, initial therapy was tailored based on biomarker profile as follows:&#xD;
Immuno-oncology patients including PD-L1 IHC combined positivity score &gt;10, high microsatellite instability, tumor mutation burden &gt;15 mutations/megabase, and/or Epstein-Barr virus positive received standard cytotherapy plus Nivolumab.&#xD;
HER2 amplified patients received standard cytotherapy plus received Trastuzumab&#xD;
EGFR amplified patients received standard cytotherapy plus ABT-806&#xD;
FGFR2 amplified patients received standard cytotherapy plus Bemarituzumab.&#xD;
MAPK/PIK3CA aberrant patients received standard cytotherapy plus Ramucirumab.&#xD;
EGFR expressing patients received standard cytotherapy plus ABT 806.&#xD;
All negative patients received standard cytotherapy plus Ramucirumab.</description>
          </group>
          <group group_id="O2">
            <title>Non-ITT: Standard Therapy</title>
            <description>For patients without monoclonal antibodies available. These patients received standard cytotherapy consisting of FOLFOX (First Line) +FOLFIRI (Second Line) +FOLTAX (Third Line)</description>
          </group>
        </group_list>
        <measure>
          <title>Completion of Biopsy and Successful, Molecularly-based Treatment Assignment</title>
          <description>Completion of biopsies with successful assignment per the treatment algorithm. Biomarker profile assays included next generation sequencing (NGS). EGFR expression was performed by selected-reaction-monitoring mass spectrometry (SRM-MS).</description>
          <population>Unit of analysis is the biopsy. Two biopsies were performed per patient, one of the primary tumor and one from a metastatic site.</population>
          <units>biopsies</units>
          <param>Number</param>
          <units_analyzed>Biopsies</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="68"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Biopsies</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="136"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="134"/>
                    <measurement group_id="O2" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adverse Event From Serial Biopsy for Second-line Treatment</title>
        <description>Number of participants with adverse events from serial biopsies of progressing metastatic disease sites (liver, lung, lymph node, peritoneum/carcinomatosis)</description>
        <time_frame>Up to 60 Months</time_frame>
        <population>This includes subset of patients administered second-line treatment</population>
        <group_list>
          <group group_id="O1">
            <title>ITT-PTS: Personalized Treatment Strategy</title>
            <description>For patients with monclonal antibiodies available, initial therapy was tailored based on biomarker profile as follows:&#xD;
Immuno-oncology patients including PD-L1 IHC combined positivity score &gt;10, high microsatellite instability, tumor mutation burden &gt;15 mutations/megabase, and/or Epstein-Barr virus positive received standard cytotherapy plus Nivolumab.&#xD;
HER2 amplified patients received standard cytotherapy plus received Trastuzumab&#xD;
EGFR amplified patients received standard cytotherapy plus ABT-806&#xD;
FGFR2 amplified patients received standard cytotherapy plus Bemarituzumab.&#xD;
MAPK/PIK3CA aberrant patients received standard cytotherapy plus Ramucirumab.&#xD;
EGFR expressing patients received standard cytotherapy plus ABT 806.&#xD;
All negative patients received standard cytotherapy plus Ramucirumab.</description>
          </group>
          <group group_id="O2">
            <title>Non-ITT: Standard Therapy</title>
            <description>For patients without monoclonal antibodies available. These patients received standard cytotherapy consisting of FOLFOX (First Line) +FOLFIRI (Second Line) +FOLTAX (Third Line)</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Event From Serial Biopsy for Second-line Treatment</title>
          <description>Number of participants with adverse events from serial biopsies of progressing metastatic disease sites (liver, lung, lymph node, peritoneum/carcinomatosis)</description>
          <population>This includes subset of patients administered second-line treatment</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Completion of Serial Biopsy for Second Line Therapy and Successful, Molecularly-based Treatment Assignment</title>
        <description>Completion of biopsy with successful treatment assignment per the treatment algorithm. Biomarker profile assays included next generation sequencing (NGS). EGFR expression was performed by selected-reaction-monitoring mass spectrometry (SRM-MS).</description>
        <time_frame>Up to 60 months</time_frame>
        <population>This includes subset of patients administered second-line treatment</population>
        <group_list>
          <group group_id="O1">
            <title>ITT-PTS: Personalized Treatment Strategy</title>
            <description>For patients with monclonal antibiodies available, initial therapy was tailored based on biomarker profile as follows:&#xD;
Immuno-oncology patients including PD-L1 IHC combined positivity score &gt;10, high microsatellite instability, tumor mutation burden &gt;15 mutations/megabase, and/or Epstein-Barr virus positive received standard cytotherapy plus Nivolumab.&#xD;
HER2 amplified patients received standard cytotherapy plus received Trastuzumab&#xD;
EGFR amplified patients received standard cytotherapy plus ABT-806&#xD;
FGFR2 amplified patients received standard cytotherapy plus Bemarituzumab.&#xD;
MAPK/PIK3CA aberrant patients received standard cytotherapy plus Ramucirumab.&#xD;
EGFR expressing patients received standard cytotherapy plus ABT 806.&#xD;
All negative patients received standard cytotherapy plus Ramucirumab.</description>
          </group>
          <group group_id="O2">
            <title>Non-ITT: Standard Therapy</title>
            <description>For patients without monoclonal antibodies available. These patients received standard cytotherapy consisting of FOLFOX (First Line) +FOLFIRI (Second Line) +FOLTAX (Third Line)</description>
          </group>
        </group_list>
        <measure>
          <title>Completion of Serial Biopsy for Second Line Therapy and Successful, Molecularly-based Treatment Assignment</title>
          <description>Completion of biopsy with successful treatment assignment per the treatment algorithm. Biomarker profile assays included next generation sequencing (NGS). EGFR expression was performed by selected-reaction-monitoring mass spectrometry (SRM-MS).</description>
          <population>This includes subset of patients administered second-line treatment</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adverse Event From Serial Biopsy for Third-line Treatment</title>
        <description>Number of participants with adverse events from serial biopsies of progressing metastatic disease sites (liver, lung, lymph node, peritoneum/carcinomatosis)</description>
        <time_frame>Up to 60 months</time_frame>
        <population>This includes subset of patients administered third-line treatment</population>
        <group_list>
          <group group_id="O1">
            <title>ITT-PTS: Personalized Treatment Strategy</title>
            <description>For patients with monclonal antibiodies available, initial therapy was tailored based on biomarker profile as follows:&#xD;
Immuno-oncology patient including PD-L1 IHC combined positivity score &gt;10, high microsatellite instability, tumor mutation burden &gt;15 mutations/megabase, and/or Epstein-Barr virus positive received standard cytotherapy plus Nivolumab.&#xD;
HER2 amplified patients received standard cytotherapy plus received Trastuzumab&#xD;
EGFR amplified patients received standard cytotherapy plus ABT-806.&#xD;
FGFR2 amplified patients received standard cytotherapy plus Bemarituzumab.&#xD;
MAPK/PIK3CA aberrant patients received standard cytotherapy plus Ramucirumab.&#xD;
EGFR expressing patients received standard cytotherapy plus ABT 806.&#xD;
All negative patients received standard cytotherapy plus Ramucirumab.</description>
          </group>
          <group group_id="O2">
            <title>Non-ITT: Standard Therapy</title>
            <description>For patients without monoclonal antibodies available. These patients received standard cytotherapy consisting of FOLFOX (First Line) +FOLFIRI (Second Line) +FOLTAX (Third Line)</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Event From Serial Biopsy for Third-line Treatment</title>
          <description>Number of participants with adverse events from serial biopsies of progressing metastatic disease sites (liver, lung, lymph node, peritoneum/carcinomatosis)</description>
          <population>This includes subset of patients administered third-line treatment</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Completion of Serial Biopsy for Third Line Therapy and Successful, Molecularly-based Treatment Assignment</title>
        <description>Completion of biopsy with successful treatment assignment per the treatment algorithm. Biomarker profile assays included next generation sequencing (NGS). EGFR expression was performed by selected-reaction-monitoring mass spectrometry (SRM-MS).</description>
        <time_frame>Up to 60 months</time_frame>
        <population>This includes subset of patients administered third-line treatment</population>
        <group_list>
          <group group_id="O1">
            <title>ITT-PTS: Personalized Treatment Strategy</title>
            <description>For patients with monclonal antibiodies available, initial therapy was tailored based on biomarker profile as follows:&#xD;
Immuno-oncology patients including PD-L1 IHC combined positivity score &gt;10, high microsatellite instability, tumor mutation burden &gt;15 mutations/megabase, and/or Epstein-Barr virus positive received standard cytotherapy plus Nivolumab.&#xD;
HER2 amplified patients received standard cytotherapy plus received Trastuzumab&#xD;
EGFR amplified patients received standard cytotherapy plus ABT-806&#xD;
FGFR2 amplified patients received standard cytotherapy plus Bemarituzumab.&#xD;
MAPK/PIK3CA aberrant patients received standard cytotherapy plus Ramucirumab.&#xD;
EGFR expressing patients received standard cytotherapy plous ABT 806.&#xD;
All negative patients received standard cytotherapy plus Ramucirumab.</description>
          </group>
          <group group_id="O2">
            <title>Non-ITT: Standard Therapy</title>
            <description>For patients without monoclonal antibodies available. These patients received standard cytotherapy consisting of FOLFOX (First Line) +FOLFIRI (Second Line) +FOLTAX (Third Line)</description>
          </group>
        </group_list>
        <measure>
          <title>Completion of Serial Biopsy for Third Line Therapy and Successful, Molecularly-based Treatment Assignment</title>
          <description>Completion of biopsy with successful treatment assignment per the treatment algorithm. Biomarker profile assays included next generation sequencing (NGS). EGFR expression was performed by selected-reaction-monitoring mass spectrometry (SRM-MS).</description>
          <population>This includes subset of patients administered third-line treatment</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>First-line Progression-free Survival</title>
        <description>Time from enrollment to progression or death during first-line treatment. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.</description>
        <time_frame>Up to 60 Months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ITT-PTS: Personalized Treatment Strategy</title>
            <description>For patients with monclonal antibiodies available, initial therapy was tailored based on biomarker profile as follows:&#xD;
Immuno-oncology patients including PD-L1 IHC combined positivity score &gt;10, high microsatellite instability, tumor mutation burden &gt;15 mutations/megabase, and/or Epstein-Barr virus positive received standard cytotherapy plus Nivolumab.&#xD;
HER2 amplified patients received standard cytotherapy plus Trastuzumab&#xD;
EGFR amplified patients received standard cytotherapy plus ABT-806&#xD;
FGFR2 amplified patients received standard cytotherapy plus Bemarituzumab.&#xD;
MAPK/PIK3CA aberrant patients received standard cytotherapy plus Ramucirumab.&#xD;
EGFR expressing patients received standard cytotherapy plus ABT 806.&#xD;
All negative patients received standard cytotherapy plus Ramucirumab.</description>
          </group>
          <group group_id="O2">
            <title>Non-ITT: Standard Therapy</title>
            <description>For patients without monoclonal antibodies available. These patients received standard cytotherapy consisting of FOLFOX (First Line) +FOLFIRI (Second Line) +FOLTAX (Third Line)</description>
          </group>
        </group_list>
        <measure>
          <title>First-line Progression-free Survival</title>
          <description>Time from enrollment to progression or death during first-line treatment. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.</description>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="68"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.2" lower_limit="7.3" upper_limit="9.6"/>
                    <measurement group_id="O2" value="6.7" lower_limit="2.9" upper_limit="10.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Objective Response to First Line Therapy</title>
        <description>Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by CT or MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.</description>
        <time_frame>Up to 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ITT-PTS: Personalized Treatment Strategy</title>
            <description>For patients with monclonal antibiodies available, initial therapy was tailored based on biomarker profile as follows:&#xD;
Immuno-oncology patients including PD-L1 IHC combined positivity score &gt;10, high microsatellite instability, tumor mutation burden &gt;15 mutations/megabase, and/or Epstein-Barr virus positive received standard cytotherapy plus Nivolumab.&#xD;
HER2 amplified patients received standard cytotherapy plus Trastuzumab.&#xD;
EGFR amplified patients received standard cytotherapy plus ABT-806.&#xD;
FGFR2 amplified patients received standard cytotherapy plus Bemarituzumab.&#xD;
MAPK/PIK3CA aberrant patients received standard cytotherapy plus Ramucirumab.&#xD;
EGFR expressing patients received standard cytotherapy plus ABT 806.&#xD;
All negative patients received standard cytotherapy plus Ramucirumab.</description>
          </group>
          <group group_id="O2">
            <title>Non-ITT: Standard Therapy</title>
            <description>For patients without monoclonal antibodies available. These patients received standard cytotherapy consisting of FOLFOX (First Line) +FOLFIRI (Second Line) +FOLTAX (Third Line)</description>
          </group>
        </group_list>
        <measure>
          <title>Objective Response to First Line Therapy</title>
          <description>Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by CT or MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>60 months</time_frame>
      <desc>Molecular arms/groups are combined for this analysis because the intent of the study was to compare the overall strategy of molecular-based treatment vs. not undertaking molecular-based therapy. Thus the number of patients with adverse events over the potential three lines of therapy is reported.</desc>
      <group_list>
        <group group_id="E1">
          <title>ITT-PTS: Personalized Treatment Strategy</title>
          <description>For patients with monclonal antibiodies available, initial therapy was tailored based on biomarker profile as follows:&#xD;
Immuno-oncology patients including PD-L1 IHC combined positivity score &gt;10, high microsatellite instability, tumor mutation burden &gt;15 mutations/megabase, and/or Epstein-Barr virus positive received standard cytotherapy plus Nivolumab.&#xD;
HER2 amplified patients received standard cytotherapy plus Trastuzumab.&#xD;
EGFR amplified patients received standard cytotherapy plus ABT-806..&#xD;
FGFR2 amplified patients received standard cytotherapy plus Bemarituzumab.&#xD;
MAPK/PIK3CA aberrant patients received standard cytotherapy plus Ramucirumab.&#xD;
EGFR expressing patients received standard cytotherapy plus ABT 806.&#xD;
All negative patients received standard cytotherapy plus Ramucirumab.</description>
        </group>
        <group group_id="E2">
          <title>Non-ITT: Standard Therapy</title>
          <description>For patients without monoclonal antibodies available.These patients received standard cytotherapy consisting of FOLFOX (First Line) +FOLFIRI (Second Line) +FOLTAX (Third Line)</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="56" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Blood and lymphatic system disorders - Other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Esophageal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Esophageal perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Esophagitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Gastrointestinal disorders - Other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Gastroparesis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Edema limbs</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Catheter related infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Pelvic infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Phlebitis infective</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Stroke</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Confusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Delirium</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal and urinary disorders - Other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Aspiration</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Surgical and medical procedures - Other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Thromboembolic event</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="68" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain - cardiac</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blurred vision</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal distenstion</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Bloating</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Dyspepsia/heartburn</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Dysphagia, esophagitis, odynophagia</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Facial pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="64" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Gastroesophagial reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Gastrointestinal disorders - Other</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Gastrointestinal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>hemorrhoidal hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Intra-abdominal hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Mucositis oral</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="52" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Periodontal disease</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Edema limbs</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Flu like symptoms</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>General disorders and administration site conditions - Other</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Localized edema</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary track infection</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Bruising</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Platelet count decreases</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Upper respiratory infection</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Hyperkalemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Flank pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Generalized muscle weakness</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Musculoskeletal and connective tissue disorder - Other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Neoplasms benign, malignant and unspecified - Other</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizzines</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Neuropathy-sensory</sub_title>
                <counts group_id="E1" subjects_affected="58" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Paresthesia</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Hallucinations</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Mood aleration - depression</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Hematuria</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Renal colic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Urinary incontinence</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Urinary tract obstruction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Aspiration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Hoarseness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Sore throat</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Palmar-plantar erythrodysesthesia synrome</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Rash acneiform</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Rash maculo-papular</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Thromboembolic event</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Daniel Catenacci, MD</name_or_title>
      <organization>University of Chicago</organization>
      <phone>2-1000</phone>
      <email>dcatenac@bsd.uchicago.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

